McDermott Will & Schulte’s healthcare and life sciences practice spans an array of sectors, including biotech, biopharmaceuticals, medtech and venture capital. The team is recognised for its expertise in R&D collaboration and licensing agreements, M&A transactions, and cross-border regulatory pathways work. The department is under the leadership of Emmanuelle Trombe, who is well regarded for the depth of her expertise in advising on joint ventures and strategic collaborations in both France and the United States. Anthony Paronneau advises on a wide array of corporate finance transactions and corporate securities.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- ‘Anne-France Moreau is remarkable for her availability, strategic thinking, and in-depth knowledge of the healthcare sector. She distinguishes herself through a highly personalized approach to cases and an ability to anticipate clients' needs. She possesses true strategic intelligence in complex negotiations.’
- 'Anthony Paronneau, Anne-France Moreau, and Emmanuelle Trombe: In my opinion, these three partners embody a versatile, complementary, and highly responsive team. They possess excellent expertise in transactional, corporate, and regulatory matters.'
- ‘Anthony Paronneau and Anne-France Moreau are recommended for their pragmatism and understanding of the market.’
- 'Anthony Paronneau has a very sharp and well-honed business acumen, enabling him to advise both very large organizations and smaller ones like ours with agility and pragmatism.’
- ‘Sophie Lafay is incredibly efficient, while Anthony Paronneau has unparalleled availability and exceptional mastery of our field of activity and the news that concerns it.'
- ‘The team has a strong command of our field and is extraordinarily efficient. They are always available and responsive to requests. They are an approachable and very pleasant team to work with. Despite being a smaller organization, we feel that we receive work of equally high quality and efficiency.’
Key clients
- Novo Nordisk
- Laboratoire Delbert
- Spotlight Medical
- Abolis Biotechnologies
- Osivax
- Novartis Groupe France SAS
- Myonex
- Owkin
- Biocorp
- MaaT Pharma
- Sensorion
- Corteria Pharmaceuticals
Work highlights
Advised Pierre Fabre on an exclusive R&D collaboration and licence agreements with RedRidge Bio, seeking to identify and develop biparatopic antibody (BPA) drug candidates against multiple targets.
Advised Orano Med on the signing of an exclusive licensing agreement with Sanofi and Radiomedix to develop AlphaMedix, a next-generation radioligand therapy for rare cancers, including neuroendocrine tumours.
Advised Novo Nordisk on the French aspects of its acquisition of Catalent.
Lawyers
Hall of Fame
The lawyers at the very top of the profession, widely known and respected by peers and clients for their longstanding involvement in market-leading work.
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Emmanuelle Trombe
Other key lawyers
Anthony Paronneau; Sophie Lafay; Anne-France Moreau